Hims & Hers Health stock outlook: Weak momentum persists after class action lawsuit raises compliance concerns

Traders Union
All News
Stocks
Hims & Hers slides 4.84% to $27.71

Highlights

A class action lawsuit alleges Hims & Hers Health misled investors on sharing health data with advertisers and pre-consultation prescription charges.
The legal proceedings raise the risk of regulatory scrutiny and possible penalties, increasing future liability concerns for Hims & Hers Health stock.
Hims & Hers Health stock trades below key short- and medium-term moving averages, with indicators signaling strong downside momentum and likely trading between $26.53 to $28.89 in the near term.

Negative sentiment rises as lawsuit triggers compliance and penalty risks

A securities class action lawsuit has been filed against Hims & Hers Health, alleging the company made false or misleading disclosures related to sharing consumer health information with third-party advertising platforms and charging customers for prescriptions before provider consultation, according to PR Newswire. These allegations have increased the risk of regulatory scrutiny and potential penalties, raising investor concerns about compliance and future liabilities. The ongoing legal proceedings are contributing to negative sentiment surrounding the stock.

Bearish momentum aligns as multiple indicators signal seller dominance

On the technical side, HIMS is trading below both the MA-20 and MA-50 on the hourly timeframe, illustrating persistent short- and medium-term downward pressure. However, the price remains above the MA-200, maintaining a bullish long-term structure, with the Ichimoku Kijun at $28.67 acting as immediate resistance. MACD and ADX both signal a sell while RSI is at 40.27, joined by Stoch RSI, CCI, and Bull/Bear Power in indicating oversold conditions and current seller dominance. The Awesome Oscillator further confirms this bearish alignment as the asset trades near session lows with heightened volatility.

Further downside likely as reversal odds remain limited by resistance

In the short term, HIMS is expected to trade within a $26.53–$28.89 range, marking the typical volatility band relative to current levels. The probability of a near-term upward reversal is considered very low, while further downside movement remains highly likely. A sustained bullish scenario would require a breakout above resistance at $28.67, whereas a decisive move below $26.53 support would reinforce bearish momentum. Sideways trading is the baseline expectation barring any major news-driven shifts.

Viktoras Karapetjanc, analyst at Traders Union, believes the recent class action lawsuit adds a significant layer of risk to Hims & Hers Health. He sees persistent negative sentiment driven by both regulatory concerns and technical weakness, despite the stock maintaining a bullish long-term structure. Macro and compliance uncertainty will likely keep investors cautious in the near term. "While the immediate trend is pressured, a breakout above $28.67 could spark renewed optimism if legal risks begin to recede."

Earlier, analysts noted that Hims & Hers Health was facing sustained short- and medium-term pressure due to increased legal and regulatory risks. The current analysis strengthens this outlook by highlighting persistent downside momentum and identifies $28.67 and $26.53 as critical technical levels for monitoring potential trend shifts.

Source of Data: HIMS Price Analysis by TU

The analysis is based on a proprietary model combining technical, on-chain, and expert data. Not investment advice. See methodology

The information is based on forecasts and does not constitute investment advice or a guarantee of future results. Market conditions may change. See our Disclaimer and Editorial Integrity for details.